

LILLY ELI & CO  
Form SD  
May 16, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM SD  
Specialized Disclosure Report

---

ELI LILLY AND COMPANY  
(Exact name of registrant as specified in its charter)

|                                                |                                       |                                      |
|------------------------------------------------|---------------------------------------|--------------------------------------|
| Indiana                                        |                                       | 35-0470950                           |
| (State or Other Jurisdiction of Incorporation) | 001-06351<br>(Commission File Number) | (I.R.S. Employer Identification No.) |

|                                          |                       |            |
|------------------------------------------|-----------------------|------------|
| Lilly Corporate Center                   |                       | 46285      |
| (Address of Principal Executive Offices) | Indianapolis, Indiana | (Zip Code) |

Karen DeHaan-Fullerton (317-586-3936)  
(Name and telephone number, including area code, of the person to contact in connection with this report)

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in the form applies:

ý Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017

#### Item 1.01. Conflict Minerals Disclosure and Report

As required by Rule 13p-1, Eli Lilly and Company (the “Company”) has concluded its conflict minerals reasonable country of origin inquiry and due diligence for the year ended December 31, 2017. In the course of this process, we have identified the following products that were potentially in the scope of Rule 13p-1 (the “Rule”): Atopica, Lenziaren, Alcaine, Vigamox, Tobrafen, Systane, Protagent, Nevanec, Maxidex, Isopto Tears, Genteal, Ciproxin HC, Ciloxan, Lacryvisc, Azopt, Azarga, Tobradex, Trobrex, and Maxitrol.

All of these products were acquired by the company as part of a transaction which closed on January 1, 2015. All of these products come from the same supplier and/or its subsidiaries. The company was unable to obtain complete documentation from the supplier on whether these products contain tin, tungsten, tantalum or gold (the “3TG Minerals”), or if relevant, about the country of origin of any 3TG Minerals incorporated into the products. As a result of our supplier’s inability to provide us with this information, we had insufficient information from this supplier and were unable to conduct any diligence to determine the mine location of origin for any 3TG Minerals that may have been used in these products.

---

As provided by the Rule, this process did not include products that were not entered into the stream of commerce in the calendar year ended December 31, 2017, or products manufactured or contracted to be manufactured by entities acquired by the Company after April 2016.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELI LILLY AND COMPANY  
(Registrant)

By: /s/ Gordon James Brooks

Name: Gordon James Brooks

Title: Chief Procurement Officer

Dated: May 14, 2018